INTRODUCTION
Cardiovascular disease remains one of the leading causes of mortality worldwide. 1 Despite significant advances in pharmacological and device-related therapies in the past two decades, such therapies only limit progression or worsening of congestive heart failure and fail to address key molecular targets related to the failing myocardium. As such, promising novel therapies are being investigated and await clinical translation. However, the discrepancies between small animal models and clinical entities have hampered the move from 'bench to bedside' . 2 Hence, translational research using clinically relevant, large animal models, which better approximate human anatomy, physiology and function are of great importance. 3 Therefore, we would like to discuss different vector delivery systems from the perspective of designing a successful cardiovascular gene therapy protocol in large animal models. Comprehensive knowledge of the specific advantages and disadvantages and possible risks of the different delivery methods is crucial to chose the appropriate approach in preclinical studies for a successful therapeutic intervention with any given strategy.
Especially the desired expression pattern should be considered carefully along with the proportion of targeted tissue. For example, the coronary antegrade injection, which mimics the physiological coronary flow, can achieve the most homogeneous distribution of injected material of all the methods. This approach has been currently used in the successful first-in-man cardiac gene therapy trial (CUPID). 4 Considering the extensive use of coronary catheterization procedures, this method can be the most ideal for the delivery of vectors, as it is easy to implement in the clinical setting. However, in a number of studies, antegrade intracoronary injection only achieved a low transfection efficacy. 5 
METHODS OF GENE DELIVERY
Antegrade coronary injection Basically, this method allows a simple and safe delivery by mimicking the physiological coronary flow pattern. The most obvious advantage of this method is the ability to perform the injection with a catheter system in a rather simple percutaneous procedure performed in the cath lab. In the setting of severe heart failure this minimal invasive approach therefore yields advantage compared with the surgical, open-chest direct myocardial injection. Considering the results from the antegrade injection of fluorescent microspheres, a very homogeneous distribution of injected material can be achieved compared with other methods (Figure 1a) .
One of the obstacles the delivered vector has to overcome is the endothelial layer of the vessel. Therefore, several agents have been applied to increase permeability and thus increase the transduction efficacy. Among these factors successfully tested were vascular endothelial growth factor, histamine and nitroglycerine have shown their efficacy. 6, 7 Especially, nitroglycerine was recently shown to significantly enhance viral transfection when administered systemically by intravenous infusion during coronary gene transfer. 8 Another approach yielding encouraging results is the combination of echo contrast microbubbles and a catheter-based viral vector delivery system. 9 Using this method, an ultrasound contrast agent with an attached vector is injected into the coronaries and will be distributed throughout the capillaries. Ultrasound then can destroy the microbubbles from the outside, thus releasing the transported substance into the surrounding tissue generating improved gene transduction. 10 With optimal placement of the delivery catheter a regional delivery to specific coronary vessels or branches can be achieved. The distribution of antegrade injected microspheres was shown to be broadly and homogeneously (Figure 2a ). 11 However, in the setting of coronary acute or chronic occlusion, the administration of a viral vector to the affected part of the heart can be hampered or impossible.
Several methods have been used to increase the transduction efficacy. Concomitant blockage of the coronary artery and venous system was shown to be an effective approach. 12 This dual blockade was shown to be superior to the single occlusion of coronary artery for the gene transfer. Other approaches use a simultaneous occlusion of coronary venous supply and the use of a circulatory device. 13, 14 Specifically designed circulatory devices can mechanically reroute the normal cardiac circulation. 15 The heart, as all other organs, is supplied with blood from the coronary arteries and returns to the venous system through the coronary sinus. A closed-loop recirculation system for myocardial gene delivery as the V-Focus achieves some desirable features. Systemic delivery of vector is reduced to avoid potential deleterious effects of transgene expression in other organs. The device establishes an isolated regional perfusion between the coronary arteries and the coronary sinus. Theoretically in closed circuit there is only loss of viral material from the circuit via the Thebesian veins, which communicate directly with the cardiac chambers and not with the coronary sinus. In most patients the actual flow by this circuit is o10%. Disadvantages of the system are the difficult and invasive setup, which limits a broader use aside from research in the clinical setting.
Retrograde coronary injection
For retrograde injection the same conduct of vessels that is used as antegrade injection (Figure 1b ). This specific mode of delivery is most suitable in the setting of severe coronary disease as the coronary vein is unaffected in most patients. 16 In combination with a specialized device for pressure regulation this approach also demonstrated an increased transfection efficacy compared with antegrade injection. 17 However, there are limitations by the pressure coming from the physiological antegrade flow. In a comparison study of different injection techniques by Hoshino et al. 11 retrograde injected microspheres were rather distributed in scattered pattern (Figure 2b) . Distribution of the virus in a broad fashion can only be achieved when the coronary artery is occluded to eliminate this pressure effect. Although even with this technique overall distribution is limited. 17 This fact limits the use of this method in a patient setting, making this a significantly more invasive approach and diminishing the described advantages.
Direct intramyocardial injection
Taking into account the existing barriers of an optimal viral transfection the direct injection avoids the limitations of the remote and intravenous injection, such as the first-pass effect, neutralizing antibodies as well as the T-cell response (Figure 1c) . Overall, an extensive first-pass clearance by the liver, lungs, spleen and kidney is limiting systemic injections. 18 Moreover, biodistribution, cellular uptake and trafficking have to be taken into account. 19 These obstacles can be addressed by injecting directly into the targeted area of the myocardium representing a major advantage of this method. Direct intramyocardial injection can be achieved either from the outside, using a surgical approach, or the inside, using a percutaneously, catheter-based approach. Overall, the approach from the outside by means of a thoracotomy is the most invasive method for vector delivery, associated with a significant risk and morbidity. This fact resembles a notable disadvantage compared with intravascular gene transfer. In a clinical setting this approach has been used in patients where a thoracotomy is performed anyway, like patients undergoing surgical revascularisation. During the procedure the target area can be clearly visualized and the injection can be performed in a controlled environment (e.g., possible leakage can be spotted easily). Expression patterns from this approach can be patchy as the injection volume as well as number of punctures that can be safely performed is limited (Figure 3) . 20 Despite the direct intramyocardial administration, a significant fraction injected material is not retained locally. 21 Moreover, in a study by Grossman et al. 21 the catheter-based needle endomyocardial injection was associated with equivalent or superior vector retention compared with an open-chest epicardial injection. Agents injected into the myocardium can exit the heart by multiple ways including immediate leakage from the needle track, effusion into lymphatic vessels as well as venous vessels. Therefore, formulations that increase retention of injected agents are an attractive approach to this problem. Gelling agents like matrigel reduce short-term leakage, but failed so far to enhance the desired long-term retention. 22 In contrast the percutaneous intramyocardial delivery is in many cases performed with highly specialized catheter system as NOGA. 23 Initially, the feasibility and safety of an endocardial injection of a viral vector using flouroscopy guidance was shown by Gwon et al. 24 The electromechanical mapping-guided approach is believed to allow a The direct injection of viral agents can be performed either percutaneously or in a surgical procedure, delivering the viral vector with repeated punctures into the targeted area. (c) In the pericardial approach the viral vector is injected either solo or with the help of a scaffold material and can potentially transfect the whole surface of the heart (d).
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superior spatial resolution and a more precise positioning the catheter tip as well as the injection needle to target an area of ischemia. 25, 26 Other imaging modalities as cardiac MRI scanners in conjunction with specialized catheters have been used as well to establish endomyocardial delivery of agents. 27 Other studies evaluated the capacity of ultrasound-targeted microbubble destruction to deliver viral vectors successfully delivering VEGF and SCF genes into the infarcted heart in mice. 28 Moreover, access can be realized by a special catheter that is advanced into the coronary sinus and target either the myocardium or coronary artery. A composite catheter system (TransAccess, TransVascular Inc., Menlo Park, CA, USA) incorporates a phased-array ultrasound tip for guidance and carries a sheathed, extendable nitinol needle. 29 Using the ultrasound probe the injection site can be carefully visualized and the needle can be advanced into the targeted area. The advantages are somehow similar as described before; disadvantage here is the limited reach of the needle depending on the anatomy.
Pericardial delivery
The pericardium encloses the whole heart, creating a small and relatively isolated fluid-filled compartment; with an slow estimated turnover time (Figure 1d ). 30 It has been investigated thoroughly for the potential delivery pathway for drug, virus and ablation catheters. 31, 32 The enclosed space was shown to be suitable candidate for local delivery of viral vectors. Adenoviral-mediated gene transfer applied to the pericardium induced expression in the myocardium. 33 Coadministration of collagenase and hyaluronidase, disrupting the pericardial cellular and extracellular barriers, increases the penetration of virus at the cost of increasing the systemic contamination and unfavorable damage to the heart structure. 34 In studies, agents like nitric oxide 
Puncture needle
Intrapericardial Catheter Figure 3 Comparison of injection sites in the small and large animal. Efficient transfection by direct myocardial injection has been shown in the rodent model of cardiac disease. However, translating these results into the large animal or even the human heart is difficult. Even by increasing the number of injection sites given the same injection volume and potency of the injected vector, in the larger heart most of the target infarct border zone area remains unaffected by the injections.
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donors were successfully applied to this area and demonstrated a systemic effect. 35 Access to the normal pericardium requires a safe and practicable minimally invasive technique. Potential damage to the heart as well as the coronary arteries has to be taken into consideration and poses a technical challenge. Access can be established either surgically 36 or in a percutaneous puncture. 37 For the percutaneous approach a transatrial, 35 transventricular 38 and subxiphoid access have been described. 37 In the subxiphoid access under fluoroscopic guidance a puncture needle was advanced toward the pericardium. After confirming successful puncture with a small bolus injection of contrast dye, a wire was placed in the pericardial space; confirming the successful puncture, clear pericardial fluid could be aspirated. Only in a few cases the fluid contained small amounts of blood, which had no implications for the safety of the procedure. Finally a 5Fr vascular sheath was placed over the wire to insert a catheter to apply the therapeutic agent ( Figure 4) . 37 Moreover, a subxiphoid access to the normal pericardium has been established with the use of an specialized device (PerDucer; Comedicus, Columbia Heights, MN, USA) 39 and a blunt tip needle device. 40 The percutaneous puncture yields some advantages to an open approach as it is less invasive, resulting in reduced scar tissue and fibrosis. Thus repeated procedures can be performed.
In order to further increase the safety of the subxiphoidal pericardiocentesis in clinical situations studies have been performed to establish the best point of puncture. An ideal approach should keep a safe distance from important structures such as left internal thoracic artery, the pleura and lung, myocardium, coronary vessels, diaphragm and intra-abdominal organs. In a human cadaveric study by Kennedy et al. 41 an immediately subxiphoidal approach appeared to be the safest compared with an approach 1.5 cm distal to the sternum and an anterior transthoracic puncture in the 5th intercostal space. The anterior transthoracic approach even lead to atrial lacerations whereas the more distal subxiphoid puncture caused the greatest number of complications, resulting from the needle entering the abdominal cavity. Although the gross anatomy between the large animal and the human is different, the general precautions about choosing the correct puncture position apply in both.
Another rare but potential deleterious complication of pericardiocentesis in clinical setting as well as in large animal research is the development of a pneumo hydropericardium. 42 Because of the rapid accumulation of air and fluid it may be fatal and can be prevented by a sophisticated procedural technique that does not allow air to enter the drainage catheter as well as a close surveillance post procedure. 43 In electrophysiology, the nonsurgical transthoracic puncture approach has been pioneered by Sosa et al. 44 to allow access for epicardial mapping procedures. The procedure is generally safe even in the setting of myocardial infarction in the large animal model. 45 Moreover, this method has also proven its value in the clinical setting and is routinely performed. From 334 patients reported by Koruth et al. 46 2-5% undergoing the procedure experienced complications, most common complications being post-procedure pericarditis and inadvertent RV puncture.
CONCLUSION AND FUTURE DIRECTIONS
For studies in the preclinical stage the choice of the most suitable delivery method for the viral vector is crucial and makes all the difference for success or failure. As more gene therapy trials and applications will be approaching the clinical stage, safety has a high priority. Developing and improving delivery methods that can provide us with the highest transduction efficiency to the largest number of cardiomyocytes is of great importance. The current vectors, mainly adeno-associated virus, will serve as parent compounds for the development of a broad range derivative agents. These derivatives will be vectors based on each of the current adeno-associated virus serotypes to target specific cell types via modified capsid ligands, sequences or tissue specific promoters. In addition increasing transduction efficacy can be accomplished by different means for each specific application approach.
Future methods will include the administration of both, improved vectors and endothelial permeabilizing agents to increase myocyte transduction efficiency. The current rapid progress in the field of bioengineering and molecular methods in conjunction with improved delivery methods set the foundation for future gene therapy trials.
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Large Animal
Small Animal Figure 4 Subxiphoid puncture of the pericardial sac. Under fluoroscopic guidance, a puncture needle is advanced under the sternum toward the pericardium. After successful puncture is confirmed a wire is placed in the pericardial space. Then a 5Fr vascular sheath is advanced over the wire and thereafter a 5Fr Judkins right catheter positioned for vector injection.
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